Glenmark drug for mild Covid patients hits market, priced at Rs 103 a pill

FabiFlu is generic version of oral antiviral favipiravir; almost 80% patients are mildly sick, market potential for the oral drug is huge

Oral antiviral drug favipiravir, which is used to treat patients with mild to moderate Covid-19 infection, will now be available in the Indian market under the brand name FabiFlu at Rs 103 per tablet. Glenmark Pharmaceuticals secured the drug regulator’s nod on Friday to manufacture and market the drug in India.  

The drug has shown promise in multiple global studies, with reduction in viral load, faster fever resolution, and faster clinical recovery. 

In India, the drug will be sold at retail chemist outlets as well as hospitals. This is an emergency use authorisation due to the pandemic situation prevalent in